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MaBACKGROUND Acute kidney injury (AKI) is a known complication after coronary revascularization, but few studies have
directly compared the incidence of AKI after coronary artery bypass surgery (CABG) or after percutaneous coronary
intervention (PCI) in similar patients.
OBJECTIVES The aim of this study was to investigate whether multivessel CABG compared with PCI as an initial
revascularization strategy is associated with a higher risk for AKI.
METHODS A retrospective analysis of patients undergoing ﬁrst documented coronary revascularization was conducted
using 2 complementary cohorts: 1) Kaiser Permanente Northern California, a diverse, integrated health care delivery
system; and 2) Medicare beneﬁciaries, a large, nationally representative older cohort. AKI was deﬁned in the Kaiser
Permanente Northern California cohort by an increase in serum creatinine of$0.3 mg/dl or$150% above baseline and in
the Medicare cohort by discharge diagnosis codes and the use of dialysis.
RESULTS The incidence of AKI was 20.4% in the Kaiser Permanente Northern California cohort and 6.2% in the
Medicare cohort. The incidence of AKI requiring dialysis was <1%. CABG was associated with a 2- to 3-fold signiﬁcantly
higher adjusted odds for developing AKI compared with PCI in both cohorts.
CONCLUSIONS AKI is common after multivessel coronary revascularization and is more likely after CABG than after
PCI. The risk for AKI should be considered when choosing a coronary revascularization strategy, and ways to prevent
AKI after coronary revascularization are needed. (J Am Coll Cardiol 2014;64:985–94) © 2014 by the American College of
Cardiology Foundation.A cute kidney injury (AKI) is a well-knowncomplication after surgical or percutaneouscoronary revascularization, ranging in prev-
alence between 1% and 30% depending on the study
population and the deﬁnition of AKI (1–5). Patients
who develop AKI not only have longer hospital
stays and higher incidence of other periproce-
dural complications but also have a higher risk for
long-term adverse outcomes, including chronic kid-
ney disease (CKD), end-stage renal disease, and
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ABBR EV I A T I ON S
AND ACRONYMS
AKI = acute kidney injury
CABG = coronary artery bypass
grafting
CKD = chronic kidney disease
eGFR = estimated glomerular
ﬁltration rate
KPNC = Kaiser Permanente
Northern California
PCI = percutaneous coronary
intervention
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986Therefore, a better understanding of the
relative risk for AKI after CABG compared
with PCI is needed to inform patients and
promote shared decision making.SEE PAGE 995Toward that end, we examined whether
isolated multivessel CABG compared with
multivessel PCI as an initial coronary revas-
cularization strategy would be associated
with a higher risk for AKI in 2 complementarypopulations: Kaiser Permanente Northern California
(KPNC), a large, integrated health care delivery sys-
tem with detailed inpatient and outpatient laboratory
and other clinical information, and Medicare beneﬁ-
ciaries, a large cohort with administrative claims data
that are representative of the older population in the
United States.
METHODS
COHORT ASSEMBLY: KPNC. KPNC cares for more
than 3.3 million persons who are representative of the
local and statewide population, apart from slightly
lower representation of the extremes of age and
income (13). To construct a cohort of patients with
isolated CABG or PCI as the initial revascularization
strategy for multivessel coronary disease, we identi-
ﬁed all health plan members $30 years of age who
underwent multivessel ($2-vessel) CABG or PCI pro-
cedures between January 1, 1996, and December 31,
2008, by International Classiﬁcation of Diseases-
Ninth Edition, codes 36.0, 36.00, 36.01, 36.02,
36.05, 36.06, 36.07, 36.09, 36.10, 36.11, 36.12, 36.13,
36.14, 36.15, 36.16, 36.17, and 36.19 and Current Pro-
cedure Terminology, Fourth Edition, codes 33510,
33511, 33512, 33513, 33514, 33516, 33517, 33518, 33519,
33521, 33522, 33523, 33530, 33533, 33534, 33535,
33536, 33572, 92973, 92980, 92981, 92982, 92984,
92995, and 92996. To capture complete data, we
restricted the analysis to patients with complete de-
mographic data and at least 12 months of continuous
membership and pharmacy beneﬁt before the
index revascularization procedure (Figure 1). Using
logistic regression with receipt of CABG or PCI as
the outcome, we calculated a propensity score (14)
for each patient using baseline sociodemographic
and clinical characteristics (Online Table 1). We
matched each patient who underwent multivessel PCI
with up to 3 patients (15) who underwent multivessel
CABG using a greedy matching algorithm that
matched propensity scores to a maximum caliper
width of 0.01 (16). We additionally required thatpatients be matched exactly on year of the index
procedure.
COHORT ASSEMBLY: MEDICARE. The Medicare
study population consisted of fee-for-service Medi-
care beneﬁciaries who underwent multivessel CABG
or multivessel PCI between 1992 and 2008. To permit
a 1-year retrospective evaluation period and to
document the presence of comorbid conditions, we
restricted the study sample to patients 66 years of age
or older with both Medicare Part A and Part B
coverage. We identiﬁed hospitalizations for coronary
revascularization from 20% Part A data and identiﬁed
patients by International Classiﬁcation of Diseases-
Ninth Revision, procedure codes and Current Proce-
dural Terminology-Fourth Edition, codes using
methods analogous to the construction of the KPNC
cohort (Figure 2). Using logistic regression with
receipt of CABG or PCI as the outcome, we calculated
a propensity score (14) for each patient using baseline
demographic and comorbid characteristics (Online
Table 2). Given the large sample size, we matched
each patient who underwent multivessel PCI with 1
patient who underwent multivessel CABG using a
greedy matching algorithm that ﬁrst matched pro-
pensity scores at 7 digits, then at 6 digits, and so
forth, down to a minimum 2-digit match (17). We
additionally required that patients be matched on
year of the index procedure, diabetes status, and age
within 1 year (Figure 2).
In both the KPNC and Medicare cohorts, we
excluded patients who had single-vessel PCI or
CABG, patients in whom the number of vessels
revascularized was unknown, and patients undergo-
ing concomitant cardiac procedures at the time
of CABG. We excluded patients with any prior
coronary revascularization, a history of organ trans-
plantation, and patients with a history of maintenance
dialysis.
BASELINE KIDNEY FUNCTION. In the KPNC cohort,
baseline serum creatinine level was deﬁned as the
most recent outpatient, non–emergency department
serum creatinine level measured with an isotope
dilution mass spectrometry–traceable assay (18)
between 7 and 365 days before the index date. For
nonurgent revascularization procedures, we also
allowed the use of a serum creatinine level measured
on the index date (19). We calculated the estimated
glomerular ﬁltration rate (eGFR) using the Chronic
Kidney Disease Epidemiology Collaboration equation
(20) and categorized patients into the following 3
groups: $60, 45 to 59, and <45 ml/min/1.73 m2. We
deﬁned patients with pre-existing CKD as having
eGFRs <60 ml/min/1.73 m2.
Kaiser Permanente Northern California
member age ≥ 30 years with any CABG
or PCI from 1/1/1996 to 12/31/2008
N=76,622
Patients with first CABG (N=28,243) or
PCI (36,239) meeting inclusion/exclusion
criteria
N=64,482
Patients with first
CABG or PCI for multivessel disease
N=32,042
Patients with isolated first CABG or PCI
for multivessel disease
N=28,735
N=22,361
N=7499
Eligible patients for
matching
N=7295
FINAL COHORT
N=2937
Excluded 12,140 patients with:
Missing or invalid demographic data (N=1349)
<12 months of continuous membership (N=7761)
<12 months of drug benefit before index date (N=241)
History of any organ transplant (N=2275)
No membership after index date (N=396)
History of CABG or PCI prior to study period (n=118)
Excluded 32,440 patients with:
Single vessel procedures
CABG: N=4794 (17%)
PCI: N=24,122 (67%)
Unknown vessel procedures
CABG: N=87 (0.3%)
PCI: N=3437 (9%)
Excluded 3307 patients with:
Concurrent valvular surgery or annuloplasty (N=2331)
Unconfirmed index hospitalization (N = 976)
Excluded 6374 patients with:
No valid baseline serum creatinine (including patients
on maintenance dialysis)
Excluded 204 patients who died during the index
hospitalization
Excluded 4358 during 3:1 propensity score
matching
Excluded 14,862 patients with:
No serum creatinine measured during the index
hospitalization (N=13,946)
AKI during the index hospitalization prior to
revascularization (N=916)
FIGURE 1 Assembly of KPNC Cohort
The ﬁnal cohort included 1,933 patients who underwent multivessel coronary artery bypass
grafting (CABG) and 1,004 patients who underwent multivessel percutaneous coronary
intervention (PCI). AKI ¼ acute kidney injury; KPNC ¼ Kaiser Permanente Northern
California.
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987In the Medicare cohort, we identiﬁed the pres-
ence or absence of baseline CKD using a previously
validated claims-based algorithm (21). This algo-
rithm has relatively low sensitivity (26%) but high
speciﬁcity (93.4%) for identifying CKD in Medicare
claims data.
OUTCOMES: AKI. In the KPNC cohort, we deﬁned the
outcome on the basis of the maximum serum creati-
nine level measured during the index hospitalization
but after the revascularization procedure. We deﬁned
AKI stages 1, 2, and 3 on the basis of modiﬁed Acute
Kidney Injury Network criteria (22): 1) a relative in-
crease in serum creatinine of $150% to 200% above
baseline or an absolute increase in serum creatinine
of $0.3 mg/dl above baseline; 2) a relative increase in
serum creatinine to more than 200% to 300% above
baseline; or 3) a relative increase in serum creatinine
to >300% above baseline or a $4.0 mg/dl absolute
increase with an acute increase of at least 0.5 mg/dl,
or the use of renal replacement therapy. Because only
2 patients had stage 2 AKI and 35 patients had stage
3 AKI, we grouped all stages of AKI together. We also
conducted a sensitivity analysis, deﬁning AKI as an
absolute increase in serum creatinine of 0.5 mg/dl
above baseline, a deﬁnition that has been used in
several previous studies of AKI (23). We excluded
patients without inpatient serum creatinine mea-
surements and patients who developed AKI during
the index hospitalization but before the revasculari-
zation procedure (Figure 1).
In the Medicare cohort, we deﬁned AKI using
any diagnosis code for 584.x during the index hospi-
talization and AKI requiring dialysis as a diagnosis
code for AKI plus a dialysis procedure code (V39.95,
V45.1, V56.0, or V56.1) (24). We also examined
whether patients who were discharged alive from the
index hospitalization required dialysis 90 days after
the index date as a measure of chronic dialysis,
deﬁned as the presence of a dialysis procedure code
on day 89, 90, or 91 (because outpatient hemodialy-
sis is usually performed thrice weekly on Monday,
Wednesday, and Friday or Tuesday, Thursday, and
Saturday).
COVARIATES. In the KPNC cohort, we identiﬁed age,
sex, self-reported race/ethnicity, and comorbid con-
ditions up to 4 years before the index date and
throughout the duration of follow-up, by using pre-
viously validated approaches based on International
Classiﬁcation of Diseases-Ninth Revision, diagnosis
and procedure codes and Current Procedural Termi-
nology-Fourth Edition, procedure codes identiﬁed
from health plan hospitalization, ambulatory, labo-
ratory, and pharmacy databases (25–31). Informationon the conditions is listed in Table 1. We also collected
selected laboratory test results up to 1 year before or
on the index date. We ascertained baseline use of the
followingmedications on the basis of information from
pharmacy records using previously validated methods
(32,33): angiotensin-converting enzyme inhibitors,
angiotensin II receptor blockers, diuretic agents,
beta-blockers, calcium-channel blockers, nitrates, hy-
dralazine, alpha-adrenergic antagonists, aldosterone
receptor antagonists, digoxin, statins, nonstatin lipid-
lowering agents, aspirin, antiplatelet agents, anti-
inﬂammatory agents, and diabetes medications.
In the Medicare cohort, we deﬁned comorbidities
using Part A and Part B data (composed of a 5%
Medicare Part A & B beneficiary, age
≥66 years with first CABG or PCI from
1/1/1992 to 12/31/2008
N=611,729
Patients with first isolated CABG
(N=206,727) or PCI (N=356,295)
N=563,022
Patients with first isolated CABG or PCI
for multivessel disease
N=259,662
Eligible patients for matching
N=251,553
FINAL COHORT
N=105,156
Excluded 146,397 patients during 1:1 propensity
score-matching
Excluded 8109 patients with end-stage renal
disease on dialysis
Excluded 303,360 patients with:
Single vessel procedures
CABG: N=7644 (3.7%)
PCI: N=292,734 (82.2%)
Unknown vessel procedures
CABG: N=95 (0.05%)
PCI: N=2887 (0.8%)
Excluded 48,707 patients with concomitant cardiac
procedures
FIGURE 2 Assembly of Fee-for-Service Medicare Cohort
The ﬁnal cohort included 52,578 patients who underwent multivessel coronary artery
bypass grafting (CABG) and 52,578 patients who underwent multivessel percutaneous
coronary intervention (PCI).
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988random sample from 1992 to 1997 and a 20% random
sample from 1998 to 2008). We deﬁned comorbid
conditions using outpatient and inpatient encounters
in the year before the index procedure and consid-
ered a comorbidity to be present if it was recorded as
a primary or secondary diagnosis code on an inpatient
admission or outpatient encounter. The characteris-
tics are listed in Table 2.
STATISTICAL ANALYSIS. All analyses were con-
ducted separately for the KPNC and Medicare cohorts.
Differences between patients undergoing CABG and
those undergoing PCI were compared using stan-
dardized differences. Standardized differences are
an alternative to p values to describe differences
between groups and are not inﬂuenced by sample
size. Standardized differences >10% represent mean-
ingful imbalance between groups (34).
For both cohorts, we calculated the odds ratio and
95% conﬁdence interval associated with CABG
compared with PCI on AKI in the propensity score–
matched cohort without additional adjustment for
speciﬁc covariates. We hypothesized that the associ-
ation of AKI with revascularization type would bemodiﬁed by baseline CKD status or diabetes mellitus
status. To address this in the KPNC cohort, we con-
ducted separate stratiﬁed analyses on the basis of
baseline eGFR ($60, 45 to 59, or <45 ml/min/1.73 m2)
and baseline diabetes mellitus status. In the Medicare
cohort, we ﬁtted models with a multiplicative inter-
action term (additive on the log scale) for the pres-
ence or absence of CKD and separately for the
presence or absence of diabetes mellitus, and we
report model estimates for those patients with and
without these factors.
We also conducted another sensitivity analysis
using the methods proposed by Lin et al. (35), to
assess whether an unmeasured confounder could
account for the observed differences in the odds of
AKI among patients undergoing CABG versus PCI.
The institutional review boards of the Kaiser
Foundation Research Institute and Stanford Univer-
sity approved the study. A waiver of the requirement
for informed consent was obtained because of the
nature of the study. All analyses were performed
using SAS versions 9.1.3 and 9.3 (SAS Institute,
Cary, North Carolina).
RESULTS
In the KPNC cohort, predictors of undergoing CABG
compared with PCI included calendar year, male
sex, and a history of unstable angina (Online
Table 1). The KPNC propensity score model had a c-
statistic of 0.856 (Online Figure 1). Of the patients
undergoing PCI, 36.5% were matched with 3 patients
undergoing CABG, 19.6% were matched with 2 pa-
tients undergoing CABG, and 43.9% were matched
with 1 patient undergoing CABG. Overall, we
matched 82% of the patients who had multivessel
PCI (1,004 of 1,222) to 1,933 patients undergoing
multivessel CABG in the KPNC cohort. In the Medi-
care cohort, predictors of undergoing CABG rather
than PCI were calendar year, age, sex, and diabetes
(Online Table 2). The Medicare propensity score
model had a c-statistic of 0.673 (Online Figure 2). We
matched 19.2% of patients on 5 to 7 digits of pro-
pensity score, 31.7% on 4 digits, 39.5% on 3 digits,
and 9.6% on 2 digits. Overall, 92% of patients who
underwent multivessel PCI were matched with pa-
tients who underwent multivessel CABG in the
Medicare cohort. Baseline characteristics in both pro-
pensity score–matched cohorts were well balanced
among patients undergoing multivessel PCI and
multivessel CABG (Tables 1 and 2).
During the index hospitalization, 20.4% of patients
in the KPNC cohort and 6.2% of patients in the
Medicare cohort developed AKI on the basis of
TABLE 1 Baseline Clinical Characteristics of the Matched KPNC
Cohort of Adults Age 30 Years or Older Undergoing Multivessel
Coronary Revascularization
Variable
CABG
(n ¼ 1,933)
PCI
(n ¼ 1,004)
Standardized
Difference
Demographics
Age, yrs
<65 39.9 39.6 0.6
65–74 33.2 30.9 4.9
$75 26.9 29.5 5.8
Women 26.9 30.5 8.0
Race
White 74.9 75.2 0.7
Black/African American 3.9 4.8 4.4
Asian/Paciﬁc Islander 13.4 12.5 2.7
Other 7.9 7.6 1.1
Hispanic ethnicity 13.9 13.1 2.3
Cardiovascular history
Prior myocardial infarction 33.4 36.9 7.3
Unstable angina 24.0 22.3 4.0
Heart failure 9.0 9.3 1.0
Cerebrovascular disease 16.7 16.4 0.8
Stroke or transient
ischemic attack
3.7 3.7 0.0
Peripheral arterial disease 3.8 3.8 0.0
Mitral/aortic valve disease 6.4 6.6 0.8
Atrial ﬁbrillation/ﬂutter 9.3 9.5 0.7
Ventricular ﬁbrillation/
tachycardia
1.2 1.4 1.8
Other medical history
Diabetes mellitus 39.2 38.0 2.5
Hypertension 68.0 68.2 0.4
Dyslipidemia 85.2 85.2 0.0
Chronic lung disease 18.4 18.3 0.3
Chronic liver disease 1.5 1.6 0.8
Diagnosed depression 13.7 14.7 2.9
Dementia 0.9 1.4 4.7
Hyperthyroidism 0.7 0.7 0.0
Hypothyroidism 11.3 12.3 3.1
Systemic cancer 11.2 11.4 0.6
Hospitalized bleed 2.3 2.2 0.7
Laboratory values
Hemoglobin, g/l 13.9  1.6 13.9  1.7 0.0
eGFR, ml/min/1.73 m2
$60 56.0 54.4 3.2
45–59 26.9 26.9 0.0
<45 (not on dialysis) 17.1 18.7 4.2
Continued in the next column
TABLE 1 Continued
Variable
CABG
(n ¼ 1,933)
PCI
(n ¼ 1,004)
Standardized
Difference
Baseline medication use
Angiotensin-converting
enzyme inhibitors
41.1 40.0 2.2
Angiotensin II receptor
blockers
8.9 9.2 1.0
Diuretic agents 40.5 41.7 2.4
Beta-blockers 58.4 56.4 4.0
Calcium-channel blockers 25.3 24.8 1.2
Nitrates 23.6 21.3 5.5
Hydralazine 2.6 3.6 5.8
Alpha-adrenergic receptor
antagonists
13.6 13.3 0.9
Aldosterone antagonists 1.2 1.2 0.0
Digoxin 6.1 6.0 0.4
Statins 55.5 54.3 2.4
Nonstatin lipid-lowering
agents
5.2 4.6 2.8
Aspirin 7.1 6.9 0.8
Antiplatelet agents 5.5 5.1 1.8
Anti-inﬂammatory agents 18.2 18.7 1.3
Diabetes medications 30.5 29.4 2.4
Values are % or mean  SD.
CABG ¼ coronary artery bypass grafting; eGFR ¼ estimated glomerular ﬁltration
rate; KPNC ¼ Kaiser Permanente Northern California; PCI ¼ percutaneous coronary
intervention.
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989cohort-speciﬁc criteria. More CABG patients than PCI
patients developed AKI, and more patients with
baseline CKD developed AKI (Figure 3, Central
Illustration). In the KPNC cohort, CABG was consis-
tently associated with 1.6 higher odds of AKI
compared with PCI overall and 1.3- to 2.0-fold higher
odds in models stratiﬁed by baseline eGFR (Table 3).
The conﬁdence intervals overlapped the point esti-
mates across eGFR and diabetes mellitus strata,indicating no clinically relevant effect modiﬁcation
by these variables in the KPNC cohort. Results were
not materially changed in sensitivity analyses in
which AKI was deﬁned as an absolute increase in
serum creatinine of $0.5 mg/dl higher than baseline
(Online Table 3). In the Medicare cohort, CABG was
associated with 2.6-fold higher odds of AKI compared
with PCI (Table 3). The magnitude of the association
was smaller for patients with baseline CKD and dia-
betes mellitus than for patients without these co-
morbid conditions.
The incidence of AKI requiring dialysis during the
index hospitalization was low in both cohorts: 0.4%
(n ¼ 12) in KPNC and 0.2% (n ¼ 252) in Medicare. The
low incidence of AKI requiring dialysis in the KPNC
cohort precluded further analysis of this outcome. In
the Medicare cohort, the incidence of AKI requiring
dialysis was higher in patients undergoing CABG
(0.4%) versus PCI (0.1%) (p < 0.0001; odds ratio: 2.66;
95% conﬁdence interval: 2.01 to 3.51) overall and in
the subset of patients with CKD: 2.9% of CABG and
1.3% of PCI patients (p < 0.0001; odds ratio: 2.3; 95%
conﬁdence interval: 1.4 to 3.8).
A signiﬁcant proportion of patients with AKI
during the index hospitalization required dialysis 90
days after the index date: 2.2% in the KPNC cohort
TABLE 2 Baseline Clinical Characteristics of the Fee-for-Service
Medicare Cohort of Adults Age 66 Years or Older Undergoing
Multivessel Coronary Revascularization
Variable
CABG
(n ¼ 52,578)
PCI
(n ¼ 52,578)
Standardized
Difference
Demographics
Age, yrs
66–70 30.0 29.8 0.4
71–75 27.6 27.9 0.7
76–80 23.1 23.3 0.5
>80 19.3 19.0 0.8
Women 41.2 42.0 1.6
Race
White 92.5 92.1 1.6
Black/African
American
4.4 4.6 1.5
Other 3.2 3.3 1.0
Metropolitan area 73.0 73.0 0.6
U.S. census region
New England 4.2 4.4 1.0
Middle Atlantic 12.0 12.3 0.9
South Atlantic 21.5 21.4 0.2
East South Central 7.1 7.3 0.8
West South Central 11.8 11.8 0.0
East North Central 20.2 20.1 0.2
West North Central 10.3 9.9 1.3
Mountain 4.6 4.6 0.0
Paciﬁc 8.4 8.3 0.4
Year of procedure
1992–1994 2.6 2.6 0.0
1995–2003 47.9 47.9 0.0
2004–2008 49.8 49.5 0.6
Comorbid conditions
Myocardial infarction on
index presentation
28.2 28.4 0.4
Tobacco abuse 18.1 19.0 2.3
Continued in the next column
TABLE 2 Continued
Variable
CABG
(n ¼ 52,578)
PCI
(n ¼ 52,578)
Standardized
Difference
Cardiovascular history
Prior myocardial
infarction
10.9 11.4 1.6
Unstable angina 30.4 29.9 1.1
Heart failure 12.5 13.2 2.1
Cerebrovascular disease 16.6 16.9 0.8
Peripheral arterial
disease
17.4 18.3 2.4
Mitral/aortic valve
disease
13.1 13.4 0.9
Atrial ﬁbrillation/ﬂutter 11.2 11.6 1.3
Ventricular ﬁbrillation/
tachycardia
2.3 2.4 0.7
Other arrhythmia 5.4 5.6 0.9
Prior ICD 0.1 0.1 0.0
Other medical history
Chronic kidney disease 5.4 5.5 0.4
Diabetes mellitus 33.3 33.3 0.0
Hypertension 78.5 78.6 0.2
Dyslipidemia 28.0 28.5 1.1
Depression 5.1 5.5 1.8
Dementia 3.0 3.0 0.0
Hypothyroidism 11.6 12.2 1.9
Systemic cancer 12.9 13.4 1.5
Arthritis 4.1 4.2 0.5
HIV/AIDS 0.02 0.02 0.0
Obesity 6.6 6.9 1.2
Intracranial hemorrhage 0.3 0.3 0.0
GI bleed 5.5 5.6 0.4
Chronic liver disease 1.1 1.2 0.9
Chronic lung disease 15.3 16.3 2.7
Anemia 11.8 12.2 1.2
Fluid/electrolyte
abnormality
6.2 6.5 1.2
Value are %.
AIDS ¼ acquired immune deﬁciency syndrome; GI ¼ gastrointestinal; HIV ¼
human immunodeﬁciency virus; ICD ¼ implantable cardioverter-deﬁbrillator;
other abbreviations as in Table 1.
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990and 2.1% in the Medicare cohort. For Medicare
patients who had AKI requiring dialysis during the
index hospitalization, 14.9% still required dialysis at
90 days.
Our results were quite robust to the effects of
potential unmeasured confounders. In the KPNC
cohort, a single unmeasured confounder could
account for the observed difference in odds of AKI
between CABG and PCI only if it decreased the odds
of AKI by at least 0.6-fold, and the prevalence of the
unmeasured confounder would need to be at least
45% in the PCI group (Online Figure 3A). The results
would have to be even more extreme in the Medicare
cohort (Online Figure 3B). In this case, a single un-
measured confounder could account for the observed
difference in odds of AKI between CABG and PCI only
if it decreased the odds of AKI by at least 0.4-fold, and
the prevalence of the unmeasured confounder would
need to be nearly 70% in the PCI group.DISCUSSION
Optimizing the decision about which type of revas-
cularization strategy to use for multivessel coronary
disease must balance the higher periprocedural
morbidity and mortality risks with the long-term
survival advantages of CABG compared with PCI,
suggested in 2 recent studies by our group (36,37)
and others (38–41). Our present analysis provides
evidence from 2 separate but complementary cohorts
that AKI during the index hospitalization should also
be considered with the other short-term risks of
CABG compared with PCI. AKI during the index
hospitalization was exceptionally common after
either type of coronary revascularization in our an-
alyses, and CABG was associated with a signiﬁcant
TABLE 3 Odds Ratios (95% Conﬁdence Intervals) for
Acute Kidney Injury for Coronary Artery Bypass Grafting
Versus Percutaneous Coronary Intervention Overall and in
Selected Subgroups
KPNC Medicare
Overall 1.60 (1.30–1.96) Overall 2.56 (2.42–2.71)
eGFR, ml/min per 1.73 m2 Chronic kidney disease
$60 1.74 (1.26–2.42) No 2.79 (2.70–2.89)
45-59 2.00 (1.32–2.98) Yes 2.10 (1.89–2.33)
<45 1.29 (0.88–1.89)
Diabetes mellitus Diabetes mellitus
No 1.66 (1.25–2.21) No 2.98 (2.89–3.10)
Yes 1.52 (1.13–2.06) Yes 2.14 (1.95–2.35)
Abbreviations as in Table 1.
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FIGURE 3 Proportion of Patients with Acute Kidney Injury in the
Kaiser Permanente Northern California and Medicare Cohorts Stratiﬁed by
Baseline Kidney Disease Status
CKD ¼ chronic kidney disease; eGFR ¼ estimated glomerular ﬁltration rate in ml/min
per 1.73 m2; other abbreviations as in Figure 1.
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9911.5- to 3-fold higher odds of AKI compared with PCI,
even after accounting for differences in baseline
characteristics and treatments between groups. In
patients with pre-procedural CKD in both cohorts,
the absolute rates of AKI were higher than in pa-
tients with preserved renal function, but the relative
odds of AKI for CABG versus PCI were similar. In the
Medicare cohort, although the incidence of AKI
requiring dialysis was low overall, it was more
common among patients with underlying CKD, and
15% of those patients still received dialysis 90 days
after the index date. Thus, when considering the
risks and beneﬁts of different revascularization
strategies, particular attention should be paid to
patients with underlying CKD. For some patients, the
risk for requiring long-term dialysis may pose such a
large quality-of-life threat that they may prefer PCI,
despite the shorter long-term survival associated
with this strategy; the opposite may be true for other
patients. Thus, an individualized, patient-centered
approach to making decisions about coronary revas-
cularization is required.
Although several studies have evaluated the inci-
dence of AKI after either CABG or PCI separately
(3,12,42–44), few studies have directly compared
CABG with PCI on the risk for AKI. In a post hoc
analysis using a propensity score–matched subset of
the Acute Catheterization and Urgent Intervention
Triage Strategy trial, participants receiving multi-
vessel CABG or PCI, the incidence of AKI (deﬁned as
a relative 25% increase or absolute 0.5 mg/dl in-
crease in serum creatinine) was 31.7% after CABG
and 14.2% after PCI (p < 0.0001) (45). No information
on baseline kidney function was reported in that
trial. We extended the ﬁndings from that clinical
trial to a more generalizable population of “real-
world” patients by leveraging data from routine
clinical practice in separate cohorts. Two studies
using information from a hospital management
company also showed a 2- to 4-fold higher odds of
AKI after CABG compared with PCI (46,47). However,
the absolute rates of AKI were very low in that study
(2% to 5%), perhaps because the method of AKI
ascertainment was not well deﬁned, and no adjust-
ments were made for differences in baseline patient
characteristics.
The rates of AKI requiring dialysis were less than
1% overall in our study but between 1% and 3% for
patients with pre-existing CKD, and AKI requiring
dialysis was more common after CABG than PCI.
Interestingly, the results from our real-world pop-
ulations are consistent with results from 2 random-
ized clinical trials. In the Future Revascularization
Evaluation in Patients With Diabetes Mellitus:Optimal Management of Multivessel Disease Trial
(40), 8 patients with diabetes and multivessel coro-
nary disease randomized to receive CABG under-
went dialysis within 30 days of revascularization,
compared with only 1 patient in the PCI group
(p ¼ 0.02). A post-hoc analysis of the Bypass Angio-
plasty Revascularization Investigation also showed a
higher crude incidence of AKI requiring dialysis after
multivessel CABG compared with PCI (3.2% and 2.2%,
respectively) (48).
STRENGTHS AND LIMITATIONS. Our analysis has
several strengths, including the use of 2 separate
patient samples. The KPNC cohort had detailed
CENTRAL ILLUSTRATION Proportion of Patients With AKI in the KPNC and
Medicare Cohorts Overall
AKI ¼ acute kidney injury; CABG ¼ coronary artery bypass grafting; KPNC ¼ Kaiser
Permanente Northern California; PCI ¼ percutaneous coronary intervention.
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992outpatient and inpatient laboratory data before the
index date, allowing more accurate deﬁnition of
baseline serum creatinine, which is paramount for the
accurate diagnosis of AKI (19). The availability of
laboratory data after the revascularization procedure
allowed us to deﬁne AKI on the basis of relatively
modest changes to the serum creatinine, which is a
much more sensitive method than the use of admin-
istrative diagnostic codes (24). This difference in
sensitivity likely accounts for the relatively higher
incidence of AKI observed in the KPNC cohort than in
the Medicare cohort. Patients in the community-
based KPNC cohort were very diverse in terms of
race/ethnicity and age. The Medicare cohort com-
plemented the KPNC cohort by providing a much
larger sample size, allowing us to capture more cases
requiring dialysis, and was drawn from a national
sample of older patients.
However, our analysis also had several limitations.
First, without information on coronary anatomy, we
were not able to distinguish patients who underwent
single-vessel PCI and then required repeat target
vessel revascularization from those who underwent
staged PCI procedures during the index hospitaliza-
tion. We therefore included only patients who un-
derwent multivessel revascularization within a single
sitting, which could have resulted in the selection of
healthier PCI patients given the higher risk nature of
the procedure. We used propensity score–matching
techniques to balance measured confounders be-
tween the CABG and PCI groups, but because the
receipt of CABG and PCI was not randomly allocated,
we cannot completely rule out residual confoundingdue to unmeasured factors. Moreover, we were un-
able to adjust for the multilevel nature of our data
and thus could not account for potential differences
among facilities in terms of the use of AKI-preventive
strategies or ascertainment of AKI, which could lead
to biased results (49). In addition, we did not have
comprehensive information on the presence and
severity of proteinuria in either cohort, which has
been shown to be an important risk factor for AKI
after coronary angiography (50). Our study period
also covered a relatively long period of time, but we
attempted to account for secular trends in revascu-
larization techniques requiring an exact match on
index year in our propensity score–matched cohorts.
Finally, information on left ventricular ejection frac-
tion, the use of cardiopulmonary bypass during
CABG, and the amount or type of contrast material
used during the PCI were unavailable, all of
which may have affected the occurrence of post-
revascularization AKI. However, the results of our
sensitivity analyses indicate that our results were
robust to the effects of any single unmeasured
confounder.
CONCLUSIONS
Our study is one of the few contemporary studies to
directly compare CABG with PCI on the incidence of
AKI. We conﬁrm the high incidence of AKI after
coronary revascularization and show that the inci-
dence increases with increasing severity of CKD.
CABG is associated with a higher odds of AKI
compared with PCI across the spectrum of CKD.
Although the rates of dialysis during the index
hospitalization were low, a substantial number of
patients continued to require outpatient dialysis 90
days later. Because more than 1 million coronary
revascularizations are performed each year in the
United States (51), procedure-related AKI may ac-
count for several hundred new patients requiring
maintenance dialysis each year, exacting a large
physical, mental, and ﬁnancial toll on patients and
the health care system. Our ﬁndings underscore the
need to include the risk for AKI when considering
revascularization strategies for multivessel coronary
disease and to continue to work to decrease the
high incidence of AKI after coronary revasculariza-
tion overall.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE 1: CABG
surgery is associated with greater odds of AKI than PCI in
patients with multivessel coronary artery disease.
COMPETENCY IN MEDICAL KNOWLEDGE 2:
Patients with CKD are at higher absolute risk for
developing AKI than those without renal impairment
but similar relative odds for AKI after CABG and PCI.
COMPETENCY IN INTERPERSONAL AND
COMMUNICATION SKILLS: When describing the risks
and beneﬁts of surgical intervention versus PCI in patients
with multivessel coronary disease, the risk for AKI should
be included, particularly for those with CKD.
TRANSLATIONAL OUTLOOK: Additional studies
are needed to determine the mechanisms of post-
revascularization AKI and develop more effective
preventive strategies.
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